Alnylam on Wednesday unveiled positive data from a late-stage clinical trial for a drug candidate known as givosiran, the company’s second rare disease treatment to rely on the Nobel Prize-winning gene-silencing technique known as RNA interference.

Givosiran takes aim at a family of rare diseases known as acute hepatic porphyrias, which can cause abdominal issues that can be fatal. The study, which included 94 people in 18 countries, found that people on the drug had fewer attacks related to the genetic disorder over the course of six months. Five other secondary measurements also showed significant improvements.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy